(0.32%) 5 116.34 points
(0.32%) 38 362 points
(0.37%) 15 986 points
(-0.94%) $83.06
(5.36%) $2.03
(0.31%) $2 354.50
(0.44%) $27.66
(4.09%) $959.85
(-0.28%) $0.932
(-0.46%) $10.97
(-0.58%) $0.796
(1.66%) $93.40
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 8.66%
@ $2.78
発行日: 13 2月 2024 @ 23:30
リターン: 0.61%
前回のシグナル: 2月 12 - 23:32
前回のシグナル:
リターン: -2.53 %
Live Chart Being Loaded With Signals
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States...
Stats | |
---|---|
本日の出来高 | 161 935 |
平均出来高 | 1.38M |
時価総額 | 503.59M |
EPS | $0 ( 2024-02-29 ) |
次の収益日 | ( $-0.100 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.35 |
ATR14 | $0.00100 (0.04%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-01 | Naftzger J. Christopher | Buy | 380 500 | Stock Option (Right to Buy) |
2024-02-01 | Naftzger J. Christopher | Buy | 95 100 | Common Shares |
2024-02-01 | Sims Karen | Buy | 403 900 | Stock Option (Right to Buy) |
2024-02-01 | Sims Karen | Buy | 101 000 | Common Shares |
2024-02-02 | Sims Karen | Sell | 4 358 | Common Shares |
INSIDER POWER |
---|
90.40 |
Last 95 transactions |
Buy: 35 682 262 | Sell: 1 766 657 |
ボリューム 相関
Arbutus Biopharma Corp 相関
10 最も正の相関 | |
---|---|
GETVV | 0.964 |
PPBT | 0.935 |
SISI | 0.934 |
DRTT | 0.929 |
WATT | 0.926 |
TPST | 0.925 |
GMBL | 0.925 |
GLMD | 0.921 |
NCBS | 0.921 |
CRTD | 0.918 |
10 最も負の相関 | |
---|---|
PPSI | -0.942 |
SLAM | -0.941 |
GSHD | -0.937 |
GFGD | -0.937 |
GASS | -0.933 |
AAPL | -0.933 |
UFPI | -0.931 |
NECB | -0.931 |
VERA | -0.93 |
UFPT | -0.93 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Arbutus Biopharma Corp 相関 - 通貨/商品
Arbutus Biopharma Corp 財務諸表
Annual | 2023 |
収益: | $18.14M |
総利益: | $16.74M (92.26 %) |
EPS: | $-0.440 |
FY | 2023 |
収益: | $18.14M |
総利益: | $16.74M (92.26 %) |
EPS: | $-0.440 |
FY | 2022 |
収益: | $39.02M |
総利益: | $37.59M (96.34 %) |
EPS: | $-0.460 |
FY | 2021 |
収益: | $10.99M |
総利益: | $0.00 (0.00 %) |
EPS: | $-0.830 |
Financial Reports:
No articles found.
Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。